Bellicum Reports Clinical Results of BPX-501 in Pediatric Leukemias at the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET
|
Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Bellicum Announces Clinical Data on BPX-501 at Presidential Symposium of the 22nd Congress of the European Hematology Association
June 23, 2017 07:00 ET
|
Bellicum Pharmaceuticals
MADRID, Spain, June 23, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited...
Bellicum Pharmaceuticals Announces Closing of Public Offering
March 30, 2017 07:00 ET
|
Bellicum Pharmaceuticals
HOUSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM) today announced the closing, on March 29, 2017, of its previously announced underwritten public offering of...
Bellicum to Report Fourth Quarter and Full Year 2016 Financial Results and Host Conference Call and Webcast on March 13, 2017
March 06, 2017 07:00 ET
|
Bellicum Pharmaceuticals
HOUSTON, March 06, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...